FY2030 Earnings Forecast for CANF Issued By HC Wainwright

Can-Fite BioPharma Ltd. (NYSE:CANF) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Can-Fite BioPharma in a research note issued to investors on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.64 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share.

A number of other research analysts have also recently weighed in on the stock. Zacks Research upgraded shares of Can-Fite BioPharma to a “hold” rating in a research note on Wednesday, May 13th. D. Boral Capital upgraded Can-Fite BioPharma from a “hold” rating to a “buy” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Can-Fite BioPharma Price Performance

CANF opened at $3.91 on Friday. The company has a 50 day simple moving average of $3.20 and a two-hundred day simple moving average of $3.73. The firm has a market cap of $2.56 million, a P/E ratio of -2.18 and a beta of 1.11. Can-Fite BioPharma has a 1-year low of $2.56 and a 1-year high of $21.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers increased its position in Can-Fite BioPharma by 42.4% in the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock worth $57,000 after purchasing an additional 11,388 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Can-Fite BioPharma in the 4th quarter worth $41,000. Finally, Sabby Management LLC increased its holdings in shares of Can-Fite BioPharma by 80.3% in the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock worth $871,000 after buying an additional 626,306 shares during the last quarter. 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).